
|Articles|March 7, 2011
Today's Daily Dose: Hemangiosarcoma
What you need to know about these indolent tumors.
Advertisement
Untitled Document
“Hemangiosarcoma is extremely indolent, so clinical signs are usually not evident until the advanced stage when metastasis has occurred. The tumors at this stage are largely resistant to chemotherapy, and standard-of-care (surgery and intensive chemotherapy) provides a median survival of little more than six months. Morbidity and mortality are usually due to acute internal hemorrhage secondary to tumor rupture.”
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on dvm360
1
FDA issues emergency use authorization for ivermectin solution to prevent screwworm in horses
2
Every 30 extra minutes under anesthesia raises complication risk in brachycephalic patients, underscoring the importance of peri-anesthetic management
3
From the CVO: I’m off the clock
4
Paws and profits: VetEvolve names first chief veterinary officer, NVA appoints two board members, and more updates
5









